Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO

Fulcrum Therapeutics, Inc.

2023-Q1 EPS reported -$0.80 revenue$1,175,000

Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.
Screening closed for Phase 3 REACH trial of losmapimod in FSHD; topline data expected Q4 2024.
Alan A. Musso appointed CFO effective Aug 7, 2023; base salary $450K, 40% target bonus, 432,800 stock option.
Licensed global rights from CAMP4 for Diamond-Blackfan Anemia; clinical hold for FTX-6058 remains unresolved.
R&D expenses fell to $17.8M from $25.0M YoY; cash runway into mid-2025.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alan A. Musso

Chief Financial Officer and Treasurer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2023-08-07
Filed: August 3, 2023, 7:59 PM ET

On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fulcrum Therapeutics, Inc. reported financial results for the second quarter of 2023.

Period: the second quarter of 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan A. Musso was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.